ReviewBiochemical pharmacology2014
Norovirus: targets and tools in antiviral drug discovery.
Review in Biochemical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study.Frontiers in chemistry · 2022Article
- Generation of Nucleic Acid Aptamer Candidates against a Novel Calicivirus Protein Target.Viruses · 2021Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Effects of Epigallocatechin-3-Gallate-Palmitate (EC16) onMicrobiology & infectious diseases (Wilmington, Del.) · 2021Article
- Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase.Journal of chemical information and modeling · 2020Article
- Viral replicons as valuable tools for drug discovery.Drug discovery today · 2020Review
- Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.Viruses · 2020Review
- Human Intestinal Enteroids to Evaluate Human Norovirus GII.4 Inactivation by Aged-Green Tea.Frontiers in microbiology · 2020Article
- HBGA binding modes and selectivity in noroviruses upon mutation: a docking and molecular dynamics study.Journal of molecular modeling · 2019Article
- Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease.Proteins · 2019Article
- Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease.European journal of medicinal chemistry · 2018Article
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Norovirus Infection in Older Adults: Epidemiology, Risk Factors, and Opportunities for Prevention and Control.Infectious disease clinics of North America · 2017Review
- Exploration of the metal coordination region of concanavalin A for its interaction with human norovirus.Biomaterials · 2017Article
- Structure(s), function(s), and inhibition of the RNA-dependent RNA polymerase of noroviruses.Virus research · 2017Review
- A universal primer-independent next-generation sequencing approach for investigations of norovirus outbreaks and novel variants.Scientific reports · 2017Article
- Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease.European journal of medicinal chemistry · 2017Article
- Structure-based exploration and exploitation of the SEuropean journal of medicinal chemistry · 2017Article
- Recent advances in understanding noroviruses.F1000Research · 2017Review
- Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.Antiviral research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of antiviral strategies to treat or prevent norovirus infections is a pressing matter. Noroviruses are the number 1 cause of acute gastroenteritis, of foodborne illness, of sporadic gastroenteritis in all age groups and of severe acute gastroenteritis in children less than 5 years old seeking medical assistance [USA/CDC]. In developing countries, noroviruses are linked to significant mortality (~200,000 children <5 years old). Noroviruses are a major culprit for the closure of hospital wards, and associated with increased hospitalization and mortality among the elderly. Transplant patients have significant risk of acquiring persistent norovirus gastroenteritis. Control and prevention strategies are limited to the use of disinfectants and hand sanitizers, whose efficacy is frequently insufficient. Hence, there is an ample need for antiviral treatment and prophylaxis of norovirus infections. The fact that only a handful of inhibitors of norovirus replication have been reported can largely be attributable to the hampering inability to cultivate human noroviruses in cell culture. The Norwalk replicon-bearing cells and the murine norovirus-infected cell lines are the available models to assess in vitro antiviral activity of compounds. Human noroviruses have been shown to replicate (to some extent) in mice, calves, gnotobiotic pigs, and chimpanzees. Infection of interferon-deficient mice with the murine norovirus results in virus-induced diarrhea. Here we review recent developments in understanding which norovirus proteins or host cell factors may serve as targets for inhibition of viral replication. Given the recent advances, significant progress in the search for antiviral strategies against norovirus infections is expected in the upcoming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.